{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Biological Agent[C307]|Gene Therapy Agent" in comments (approximate match)
Status:
Investigational
Source:
NCT00074737: Phase 2 Interventional Completed Acute Myelogenous Leukemia
(2004)
Source URL:
Class:
NUCLEIC ACID
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00761280: Phase 3 Interventional Terminated Anaplastic Astrocytoma
(2008)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00565058: Phase 2 Interventional Completed Acute Myeloid Leukemia
(2007)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT02947867: Phase 2/Phase 3 Interventional Unknown status Ischaemic Central Retinal Vein Occlusion
(2017)
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2017)
First approved in 2017
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01436968: Phase 3 Interventional Active, not recruiting Prostate Cancer
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04105374: Phase 2/Phase 3 Interventional Withdrawn Anaplastic Astrocytoma
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03294083: Phase 1/Phase 2 Interventional Active, not recruiting Renal Cell Carcinoma
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE